

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leach et al.
Serial No.: 10/510,467 Group Art Unit: 1624
Filed: 25 May 2005 Examiner: Deepak R RAO
For: N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE
AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTEROSCLEROSIS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REPLY TO REQUIREMENT TO
RESTRICT UNDER 35 U.S.C. § 121**

Sir:

This paper is in response to the Restriction Requirement dated 18 March 2008, setting forth a thirty (30) day shortened statutory period for reply. Claims 1-11, 13 and 16-17 are pending in the application. Claims 1-11, 13 and 16-17 are subject to restriction and/or election requirement. As this response is timely filed within the shortened statutory period for response of thirty (30) days, no fee is required. Please charge any additional fees relating to this paper to Deposit Account No. 19-2570.

Restriction to one of the following invention was required under 35 U.S.C. 121:

I. Claims 1-3, 6-11, 13 and 16-17, drawn to compounds of formula (I) wherein X is N, Corresponding process of preparation, composition and method of use.

II. Claims 1-5, 8-11, 13 and 16-17, drawn to compounds of formula (I) wherein X is CH, Corresponding process of preparation, composition and method of use.

Applicants hereby elects Group I with out traverse

Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,

/JamesM Kanagy/

James M. Kanagy
Attorney for Applicants
Registration No. 29,550

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014
Facsimile (610) 270-5090